Table 2.
Mutations and variant allele fractions detected in post-operative ctDNA+ patients.
| Patient ID | Gene | Mutation | Variant Allele Fraction in tumor (%) | Variant AlleleFraction in ctDNA (%) | Limit of detection of the assay | Time between collection andrecurrence (months) |
|---|---|---|---|---|---|---|
| Nonrecurrent patients | ||||||
| 1470 | TP53 | c.524G>A | 70.5 | 0.07 | 0.055 | |
| Recurrent patients | ||||||
| 41 | KRAS | c.35G>T | 60.3 | 6.8 | 0.044 | 0.3 |
| 536 | TP53 | c.527G>T | 45.6 | 0.022 | 0.011 | 1 |
| 886 | KRAS | c.35G>A | 27.3 | 0.15 | 0.061 | 12.6 |
| 923 | BRAF | c.1799T>A | 31.9 | 1.31 | 0 | 54.1 |
| 1182 | TP53 | c.817C>T | 49.1 | 0.049 | 0.02 | 3.3 |
| 1496 | KRAS | c.35G>A | 16.8 | 0.12 | 0.061 | 18.2 |
| 1573 | KRAS | c.35G>A | 34.4 | 0.28 | 0.061 | 13.4 |
| 1857 | KRAS | c.35G>A | 11.4 | 15.9 | 0.061 | 4.2 |
| 1905 | BRAF | c.1799T>A | 18.3 | 0.37 | 0.048 | 29.9 |